Bryan Doherty, MD1, William Palmer, MD2, Allison Zhang, MD1, William M. Briggs, PhD1, Lisa A. Marks, MLS, AHIP3, Smruti R. Mohanty, MD, MS4
1New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY; 2Mayo Clinic, Jacksonville, FL; 3Mayo Clinic, Scottsdale, AZ; 4New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY
Introduction: Acute portal vein thrombosis (PVT) is a rare diagnosis frequently associated with cirrhosis. Clinical presentation is typically nonspecific with potentially catastrophic short-term complications including sepsis, bowel infarction, and death. Management strategies differ for acute and chronic PVT. Guidelines for treating acute PVT recommend immediate initiation of systemic anticoagulation. Direct and indirect thrombolytic therapy (mechanical thrombectomy and fibrinolytic therapy) may be used in combination with systemic anticoagulation in the setting of bowel ischemia or as an adjunct in patients with a contraindication to systemic anticoagulation. We aimed to assess the success of thrombolytic therapy for non-malignant acute PVT and to compare the success of direct versus indirect thrombolytic therapy.
Methods: This was a systematic review and meta-analysis in which two independent librarians searched the following databases from the date of inception to March 2019: Ovid Medline, Ovid Embase, Scopus and Web of Science. All included studies provided technical and clinical success data, as well as adverse events, and technique(s) used for the intervention of non-malignant acute PVT.
Results: The two independent database searches yielded 143 citations, of which 79 duplicates were removed leaving a total of 64 references and 11 were included in our analyses. The overall success rate of thrombolytic therapy using the random effects model was 83% (95%CI: 0.67, 0.92; P = < 0.01; I 2 = 61%). The overall clinical improvement rate of thrombolytic therapy using the fixed effects model was 95% (95%CI: 0.88, 0.98; P = 0.73; I 2 = 0%). The overall mortality of thrombolytic therapy using the fixed effects model was 5% (95%CI: 0.03, 0.11; P = 0.92; I 2 = 0%). In the direct and indirect thrombolytic groups, the rate of technical success was 84% and 52%, respectively, with an odds ratio of 3.37 (95%CI (0.96, 7.67), p-value = 0.127).
Discussion: Our analysis demonstrates that thrombolytic therapy successfully eliminates non-malignant acute PVTs with low rates of mortality. Direct thrombolysis may produce increased efficacy compared to indirect thrombolytic therapy. Larger prospective randomized trials comparing these interventions are warranted.
Citation: Bryan Doherty, MD; William Palmer, MD; Allison Zhang, MD; William M. Briggs, PhD; Lisa A. Marks, MLS, AHIP; Smruti R. Mohanty, MD, MS. P0625 - THROMBOLYTIC THERAPY FOR ACUTE NON-MALIGNANT PORTAL VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Program No. P0625. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.